Loading...
Market
What will be the FDA approval status of Bel-sar for choroidal melanoma by December 31, 2025?
2
Resolution / Starting Odds
Approved • 25%
Not Approved • 25%
Approval Pending • 25%
Withdrawn • 25%
FDA official announcements and Aura Biosciences press releases
Story
Aura Biosciences Reports Positive Phase 2 Results for Bel-sar in Choroidal Melanoma, 80% Tumor Control Rate
Sep 12, 2024, 11:50 AM
Aura Biosciences has announced positive Phase 2 end-of-study results for its drug Bel-sar, which is being evaluated as a first-line treatment for early-stage choroidal melanoma. The study demonstrated an 80% tumor control rate and a 90% visual acuity preservation rate, with a highly favorable safety profile. These promising results have led to a 7.5% increase in Aura Biosciences' stock price pre-market.
View original story
Similar markets
Approved by FDA • 25%
Approved by EMA • 25%
Approved by both FDA and EMA • 25%
Not approved • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
Full Approval • 25%
Accelerated Approval • 25%
Conditional Approval • 25%
No Approval • 25%
